Severe cutaneous Candida infection during natalizumab therapy in multiple sclerosis.
Gutwinski
S
S
Department of Neurology, Jewish Hospital Berlin, Heinz-Galinski-Str. 1, 13347 Berlin, Germany. stefan.gutwinski@jkb-online.de
Erbe
S
S
Münch
C
C
Janke
O
O
Müller
U
U
Haas
J
J
D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D002175:Candida / Q000502:physiology*; D005260:Female; D006801:Humans; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000188:drug therapy*; D000069442:Natalizumab; D012189:Retrospective Studies; D013207:Staphylococcal Skin Infections / Q000209:etiology*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069442:Natalizumab